RE:RE:RE:RE:Why PP at lower price!I take responsibility for buying into 20,000 * $12,000 potential monthly revenue stream. I, nor anybody here, came up with the 20,000 manufacturing capacity figure, nor the USD $12,000 price. I took into account the risk by imagining the revenue stream at 1,000 monthly unit sale, despite the initiatives to secure a 20,000 manufacturing capacity while they knew better than us of all the supply challenges, etc. I take full responsibility for giving company issued information amount of (discounted) credit. I don't blame the CEO for my decisions, I hold the CEO responsible for the information he put out publicly through many different means. Are you honestly going to pull that card in the KNR context? Are you going to honestly say that when a company sees a demand of a few hundred or a couple of thousand units but seeks and publicly discloses that it is securing capacity to 20,000 monthly units (240,000 annually), that investors should not have even assumed that 10,000 units are reasonably in the bag? And at 10,000 units without the core business and cartridges, the revenues are $120 million while the market cap is $200 million? So, with 10,000 out of 240,000 units, how do you come up with a "huge downside potential" that we are now seeing? Please explain that to me without saying that we should placed zero reliance on the publicly disseminated information.
LeeGoomis wrote: who is blaming the institutional investors? Their were potential problems with biocloud all along, no matter what ghezzi was saying. Alot of people were talking about those problems on these boards, as an investor you should of been aware of those potential problems. When you buy stocks after 1000% runs their is always a huge risk to your investment. Sure Ghezzi overestimated the demand of the product, but the fact is it was an uproven product that didnt exist more than 6 months. Buying at 5 dollars was extremely speculative investment with huge downside potential, and now we are seeing it. The company had 15 million in revenue with a 300 million market cap at those prices, at some point you have to take responsibility for your investment decisions, and not blame everything on the ceo.